Furthermore, it is considered an ICD inducer, as it (1) prevents breast cancer tumour establishment (216) (2); promotes HSP90 exposure, DC maturation and antitumour T-cell response against myeloma cells from patients (217) (3); triggers calreticulin exposure, induces DCs maturation (increase of CD83 and CD86) and the antitumour T-cell response, increasing the number of effector memory CD4+ and CD8+ cells (4); the in vivo vaccination with bortezomib-treated cells prevents tumour establishment and promotes long-term antitumour memory against multiple myeloma cells (218). Here, CD4 is linked to plasma cell myeloma.